Cancer Immunology, Immunotherapy

, Volume 31, Issue 3, pp 182–186 | Cite as

Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin

  • W. H. De Jong
  • E. C. De Boer
  • A. P. M. Van Der Meijden
  • P. Vegt
  • P. A. Steerenberg
  • F. M. J. Debruyne
  • E. J. Ruitenberg
Original articles


Urine samples were obtained from patients with superficial bladder cancer after immunotherapy with bacillus Calmette-Guérin (BCG). The patients were repeatedly (once a week for 6 consecutive weeks) treated with intravesical administration of approximately 5 × 108 culturable particles of BCG. Some patients received more than six BCG instillations. The urine samples were investigated for the presence of interleukin-2 (IL-2) in an in vitro bioassay using a murine cytotoxic T cell line (CTTL-16) that shows IL-2-dependent growth. Preliminary experiments indicated the presence of inhibitory factors in the urine. This inhibitory activity was abolished after 24 h dialysis. In a neutralization assay with both polyvalent and monoclonal anti-(human IL-2) antibody it was demonstrated that there was indeed IL-2 in the urine samples. In 8 of 11 patients the presence of IL-2 in the urine was demonstrated. The IL-2 production was directly related to the BCG administration as samples obtained just before the BCG instillation were always negative. In IL-2-positive samples a maximum level of IL-2 was observed between 2 h and 6 h after the BCG instillation. In urine samples obtained 24 h after the BCG IL-2 was not detected. In most patients the urine became positive after the third or fourth BCG instillation


Cancer Patient Cancer Research Inhibitory Activity Bladder Cancer Urine Sample 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Böhle A, Nowc C, Ulmer A, Musehold J, Flad F (1989) Detection of urinary Il-1, IL-2, and TNF after intravesical BCG therapy. In: Debruyne FMJ (ed) Symposium on New Trends in Urology, September 13–16 1989 Abstract book, University of Nijmegen Medical School, Nijmegen, The Netherlands. p 40Google Scholar
  2. 2.
    Coe JE, Felman JD (1966) Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder. Immunology 10: 127PubMedGoogle Scholar
  3. 3.
    Debruyne FMJ, Van der Meijden AMP, Geboers ADH, Franssen MPH, Van Leeuwen MJW, Steerenberg PA, De Jong WH, Ruitenberg EJ (1988) BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of a randomized prospective trial. Urology [Suppl] 31: 20Google Scholar
  4. 4.
    De Jong WH, Steerenberg PA, Kreeftenberg JG, Tiesjema RH, Kruizinga W, Van Noorle-Jansen LM, Ruitenberg EJ (1984) Experimental screening of BCG preparations produced for cancer immunotherapy. Safety and immunostimulating and antitumor activity of four consecutively produced batches. Cancer Immunol Immunother 17: 18PubMedGoogle Scholar
  5. 5.
    De Jong WH, Teppema JS, Wagenaar Sj Sc, Paques M, Steerenberg PA, Ruitenberg EJ (1986) Histological evaluation of immunologically mediated tumor regression of the line 10 guinea pig hepatocarcinoma. Virchows Arch [B] 50: 249Google Scholar
  6. 6.
    De Jong WH, Steerenberg PA, Ruitenberg EJ (1987) Bacillus Calmette-Guérin (BCG) and its use for cancer immunotherapy. Res Monogr Immunol 11: 283Google Scholar
  7. 7.
    Guinan P, Shaw M, Ray P (1986) Histopathology of BCG and thiotepa treated bladders. Urol Res 14: 211PubMedGoogle Scholar
  8. 8.
    Haaff EO, Dresner SM, Kelley DR, Ratliff TL, Shapiro A, Catalona WJ (1985) Role of immunotherapy in the prevention of recurrence and invasion of urothelial bladder tumors: a review. World J Urol 3: 76Google Scholar
  9. 9.
    Haaff EO, Catalona WJ, Ratliff TL (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136: 970PubMedGoogle Scholar
  10. 10.
    Hanna MG Jr, Zbar B, Rapp HJ (1972) Histopathology of tumor regression after intralesional injection ofMycobacterium bovis: I. Tumor growth and metastasis. J Natl Cancer Inst 48: 1441PubMedGoogle Scholar
  11. 11.
    Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM (1985) Intravesical bacillus Calmette Guérin therapy for superficial bladder cancer: effect of Bacillus Calmette-Guérin viability on treatment results. J Urol 134: 48PubMedGoogle Scholar
  12. 12.
    Klein WR, Ruitenberg EJ, Steerenberg PA, De Jong WH, Kruizinga W, Misdorp W, Bier J, Tiesjema RH, Kreeftenberg JG, Teppema JS, Rapp HJ (1982) Immunotherapy by intralesional injection of BCG cell walls or live BCG in bovine ocular squamous cell carcinoma: a preliminary report. J Natl Cancer Inst 69: 1095PubMedGoogle Scholar
  13. 13.
    Klein WR, Bras GE, Misdorp W, Steerenberg PA, De Jong WH, Tiesjema RH, Kersjes AW, Ruitenberg EJ (1986) Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomized clinical trial. Cancer Immunol Immunother 21: 133PubMedGoogle Scholar
  14. 14.
    Lage JM, Bauer WC, Kelley DR, Ratliff TL, Catalona WJ (1986) Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guérin treatment of superficial bladder cancer. J Urol 135: 916PubMedGoogle Scholar
  15. 15.
    Lamm DL, Thor DE, Harris SL, Reyna JA, Stogdill VD, Radwin HM (1980) Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 124: 38PubMedGoogle Scholar
  16. 16.
    Mitchell MS, Murahata RI (1979) Modulation of immunity by bacillus Calmette-Guérin (BCG). Pharmacol Ther 4: 329.PubMedGoogle Scholar
  17. 17.
    Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 116: 180PubMedGoogle Scholar
  18. 18.
    Mulé JJ, Yang JC, Afreniere RL, Shu S, Rosenberg SA (1987) Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin 2. J Immunol 139: 285PubMedGoogle Scholar
  19. 19.
    Pizza G, Severini G, Mennitti D, DeVinci C, Corrado F (1984) Tumor regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int J Cancer 34: 359PubMedGoogle Scholar
  20. 20.
    Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity J Urol 137: 155PubMedGoogle Scholar
  21. 21.
    Ratliff TL, Haaff EO, Catalona WJ (1986) Interleukin 2 production during intravesical bacillus Calmette-Guérin therapy for bladder cancer. Clin Immunol Immunopathol 40: 375PubMedGoogle Scholar
  22. 22.
    Ratliff TL, Shapiro A, Catalona WJ (1986) Inhibition of murine bladder tumor growth by bacille Calmette-Guérin; lack of a role of natural killer cells. Clin Immunol Immunopathol 41: 108PubMedGoogle Scholar
  23. 23.
    Reitsma D, Guinan P, Lamm DL, Khanna OP, Brosman SA, De Kernion JB, Williams RD, Simpson G, Hanna MG (1989) Long term effect of intravesical bacillus Calmette-Guérin (BCG). Tice strain on flat carcinoma in situ of bladder cancer. In: Debruyne FJM, Denis L, Van der Meijden APM (eds) Progress in clinical and Biological Research 310: EORTC Genitourinary Group Monograph 6: BCG in superficial bladder cancer. Alan R. Liss, New York, p 171Google Scholar
  24. 24.
    Rosenberg SA (1988) Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 9: 58PubMedGoogle Scholar
  25. 25.
    Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guérin and its correlation with bacillus Calmette Guérin viability and natural killer cell activity. Cancer Res 43: 1611PubMedGoogle Scholar
  26. 26.
    Van der Meijden APM, De Jong WH, De Boer EC, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ (1989) Immunological aspects of intravesical administration of bacillus Calmette-Guérin (BCG) in the guinea pig. Urol Res 17: 47PubMedGoogle Scholar
  27. 27.
    Van der Meijden APM, De Jong WH, Steerenberg PA, Walvoort HC, De Boer EC, Debruyne FMJ, Ruitenberg EJ (1988) Intravesical BCG administration in the guinea pig. A histomorphological study. Virchows Arch [B] 55: 207Google Scholar
  28. 28.
    Watson J, Mochizuki D, Gillis S (1980) T cell growth factors: interleukin 2. Immunol Today 1: 113Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • W. H. De Jong
    • 1
  • E. C. De Boer
    • 1
  • A. P. M. Van Der Meijden
    • 2
    • 3
  • P. Vegt
    • 4
  • P. A. Steerenberg
    • 1
  • F. M. J. Debruyne
    • 2
  • E. J. Ruitenberg
    • 1
  1. 1.Laboratory for PathologyNational Institute of Public Health and Environmental ProtectionBilthovenThe Netherlands
  2. 2.Department of UrologyUniversity Hospital NijmegenNijmegenThe Netherlands
  3. 3.Department of UrologyGrootziekengasthuis's-Hertogenbosch
  4. 4.Department of UrologySt. Elisabeth HospitalLeiderdorp

Personalised recommendations